Scope The cardioprotective role of resveratrol as part of the human diet is not yet clear. Our aim was to investigate the effect of a grape supplement containing 8 mg resveratrol in oxidized LDL (LDLox), apolipoprotein‐B (ApoB), and serum lipids on statin‐treated patients in primary cardiovascular disease prevention (PCP). Methods and results A triple‐blind, randomized, placebo‐controlled trial was conducted. Seventy‐five patients (three parallel arms) consumed one capsule (350 mg) daily for 6 months containing resveratrol‐enriched grape extract (GE‐RES, Stilvid®), grape extract (GE, similar polyphenolic content but no resveratrol), or placebo (maltodextrin). After 6 months, no changes were observed in the placebo group and only LDL cholesterol (LDLc) decreased by 2.9% (p = 0.013) in the GE group. In contrast, LDLc (−4.5%, p = 0.04), ApoB (−9.8%, p = 0.014), LDLox (−20%, p = 0.001), and LDLox/ApoB (−12.5%, p = 0.000) decreased in the Stilvid® group, whereas the ratio non‐HDLc (total atherogenic cholesterol load)/ApoB increased (8.5%, p = 0.046). No changes were observed in hepatic, thyroid, and renal function. No adverse effects were observed in any of the patients. Conclusion This GE‐RES reduced atherogenic markers and might exert additional cardioprotection beyond the gold‐standard medication in patients from PCP. The presence of resveratrol in the GE was necessary to achieve these effects.